Q3169751 (Q3169751): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Abstract Pressure ulcers (PPUs) are one of the most common complications affecting patients with spinal cord injury (ML) despite different preventive strategies. PPPs are also the main cause of unplanned hospitalisation in patients with ML, resulting in an increase in hospital stay and expenses. Recent studies show how autologous cell therapies could be an option to treat pressure ulcers in patients with spinal cord injury, avoiding major surgic...) |
||||||||||||||
| Property / summary | |||||||||||||||
Abstract Pressure ulcers (PPUs) are one of the most common complications affecting patients with spinal cord injury (ML) despite different preventive strategies. PPPs are also the main cause of unplanned hospitalisation in patients with ML, resulting in an increase in hospital stay and expenses. Recent studies show how autologous cell therapies could be an option to treat pressure ulcers in patients with spinal cord injury, avoiding major surgical intervention. Main objectives: 1- Determine whether autologous adipose tissue in patients with ML and PUP can be considered as a reliable source of endothelial stem cells and progenitor cells (MSC and ECFC) for therapeutic use. 2- Design a protocol for the extraction, expansion, cryoconservation and reintroduction of these cellular populations in LM, using criteria established by the European Medicines Agency. 3- Determine whether the use of this combination of cells is safe and can improve current results, using an animal model of rat with UPP. — Methodology: 1- Isolation and characterisation of MSCs and ECFCs from adipose tissue in patients with ML and PPU. 2- Efficacy and safety test (combined use MSC/ECFC as autologous cell therapy), in a rat animal model with PUP (preclinical study). (English) | |||||||||||||||
| Property / summary: Abstract Pressure ulcers (PPUs) are one of the most common complications affecting patients with spinal cord injury (ML) despite different preventive strategies. PPPs are also the main cause of unplanned hospitalisation in patients with ML, resulting in an increase in hospital stay and expenses. Recent studies show how autologous cell therapies could be an option to treat pressure ulcers in patients with spinal cord injury, avoiding major surgical intervention. Main objectives: 1- Determine whether autologous adipose tissue in patients with ML and PUP can be considered as a reliable source of endothelial stem cells and progenitor cells (MSC and ECFC) for therapeutic use. 2- Design a protocol for the extraction, expansion, cryoconservation and reintroduction of these cellular populations in LM, using criteria established by the European Medicines Agency. 3- Determine whether the use of this combination of cells is safe and can improve current results, using an animal model of rat with UPP. — Methodology: 1- Isolation and characterisation of MSCs and ECFCs from adipose tissue in patients with ML and PPU. 2- Efficacy and safety test (combined use MSC/ECFC as autologous cell therapy), in a rat animal model with PUP (preclinical study). (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Abstract Pressure ulcers (PPUs) are one of the most common complications affecting patients with spinal cord injury (ML) despite different preventive strategies. PPPs are also the main cause of unplanned hospitalisation in patients with ML, resulting in an increase in hospital stay and expenses. Recent studies show how autologous cell therapies could be an option to treat pressure ulcers in patients with spinal cord injury, avoiding major surgical intervention. Main objectives: 1- Determine whether autologous adipose tissue in patients with ML and PUP can be considered as a reliable source of endothelial stem cells and progenitor cells (MSC and ECFC) for therapeutic use. 2- Design a protocol for the extraction, expansion, cryoconservation and reintroduction of these cellular populations in LM, using criteria established by the European Medicines Agency. 3- Determine whether the use of this combination of cells is safe and can improve current results, using an animal model of rat with UPP. — Methodology: 1- Isolation and characterisation of MSCs and ECFCs from adipose tissue in patients with ML and PPU. 2- Efficacy and safety test (combined use MSC/ECFC as autologous cell therapy), in a rat animal model with PUP (preclinical study). (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 17:39, 12 October 2021
Project Q3169751 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3169751 in Spain |
Statements
65,600.0 Euro
0 references
82,000.0 Euro
0 references
80.0 percent
0 references
1 January 2019
0 references
31 March 2022
0 references
FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS
0 references
39°51'21.85"N, 4°1'26.26"W
0 references
45168
0 references
Resumen Las úlceras por presión (UPP) son una de las complicaciones más frecuente que afecta a los pacientes con lesión medular (LM) a pesar de las distintas estrategias preventivas. Las UPP son también la principal causa de hospitalización no planificada en pacientes con LM, lo que resulta en un aumento de la estancia hospitalaria y los gastos derivados de la misma. Estudios recientes muestran como las terapias basadas en células autólogas podrían ser una opción para tratar las úlceras por presión en pacientes con lesión medular, evitando la intervención quirúrgica mayor. Objetivos principales: 1- Determinar si el tejido adiposo autólogo de pacientes con LM y UPP puede considerarse como una fuente fiable de células madre y células progenitoras endoteliales (MSC y ECFC), para uso terapéutico. 2- Diseñar un protocolo para la extracción, expansión, crioconservación y reintroducción de estas poblaciones celulares en LM, utilizando criterios establecidos por la Agencia Europea de Medicamentos. 3- Determinar si el uso de esta combinación de células es seguro y puede mejorar los resultados actuales, usando para ello un modelo animal de rata con UPP. - Metodología: 1- Aislamiento y caracterización de las MSC y ECFC procedentes de tejido adiposo de pacientes con LM y UPP. 2- Ensayo de eficacia y seguridad (uso combinado MSC/ECFC como terapia celular autóloga), en un modelo de animal de rata con UPP (estudio Preclínico). (Spanish)
0 references
Abstract Pressure ulcers (PPUs) are one of the most common complications affecting patients with spinal cord injury (ML) despite different preventive strategies. PPPs are also the main cause of unplanned hospitalisation in patients with ML, resulting in an increase in hospital stay and expenses. Recent studies show how autologous cell therapies could be an option to treat pressure ulcers in patients with spinal cord injury, avoiding major surgical intervention. Main objectives: 1- Determine whether autologous adipose tissue in patients with ML and PUP can be considered as a reliable source of endothelial stem cells and progenitor cells (MSC and ECFC) for therapeutic use. 2- Design a protocol for the extraction, expansion, cryoconservation and reintroduction of these cellular populations in LM, using criteria established by the European Medicines Agency. 3- Determine whether the use of this combination of cells is safe and can improve current results, using an animal model of rat with UPP. — Methodology: 1- Isolation and characterisation of MSCs and ECFCs from adipose tissue in patients with ML and PPU. 2- Efficacy and safety test (combined use MSC/ECFC as autologous cell therapy), in a rat animal model with PUP (preclinical study). (English)
12 October 2021
0 references
Toledo
0 references
Identifiers
PI18_00427
0 references